JP2005534308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005534308A5 JP2005534308A5 JP2004524915A JP2004524915A JP2005534308A5 JP 2005534308 A5 JP2005534308 A5 JP 2005534308A5 JP 2004524915 A JP2004524915 A JP 2004524915A JP 2004524915 A JP2004524915 A JP 2004524915A JP 2005534308 A5 JP2005534308 A5 JP 2005534308A5
- Authority
- JP
- Japan
- Prior art keywords
- adamts4 protein
- modified
- protein
- modified adamts4
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000051403 ADAMTS4 Human genes 0.000 claims 39
- 108091005664 ADAMTS4 Proteins 0.000 claims 39
- 108010003059 aggrecanase Proteins 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39872102P | 2002-07-29 | 2002-07-29 | |
| PCT/US2003/023484 WO2004011637A2 (en) | 2002-07-29 | 2003-07-29 | Modified adamts4 molecules and method of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005534308A JP2005534308A (ja) | 2005-11-17 |
| JP2005534308A5 true JP2005534308A5 (enExample) | 2006-09-14 |
Family
ID=31188463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004524915A Pending JP2005534308A (ja) | 2002-07-29 | 2003-07-29 | 修飾ａｄａｍｔｓ４分子およびその使用法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7118902B2 (enExample) |
| EP (1) | EP1525307A2 (enExample) |
| JP (1) | JP2005534308A (enExample) |
| CN (1) | CN1681920A (enExample) |
| AU (1) | AU2003261269A1 (enExample) |
| BR (1) | BR0313083A (enExample) |
| CA (1) | CA2492444A1 (enExample) |
| IL (1) | IL166535A0 (enExample) |
| MX (1) | MXPA05000959A (enExample) |
| WO (1) | WO2004011637A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002304108B2 (en) | 2001-06-01 | 2004-04-22 | Mitsubishi Paper Mills Limited | Total heat exchange element-use paper |
| SG160194A1 (en) | 2002-02-05 | 2010-04-29 | Wyeth Corp | Truncated aggrecanase molecules |
| MXPA05000959A (es) * | 2002-07-29 | 2005-05-16 | Wyeth Corp | Moleculas adamts4 modificadas y metodo de uso de las mismas. |
| US7696307B2 (en) * | 2004-04-12 | 2010-04-13 | The Trustees Of The University Of Pennsylvania | Function and regulation of ADAMTS-1 |
| EP1737973A1 (en) * | 2004-04-16 | 2007-01-03 | Wyeth | Truncated adamts molecules |
| MX2008002323A (es) * | 2005-08-25 | 2008-03-18 | Wyeth Corp | Estructura de agrecanasa. |
| CN101300345A (zh) | 2005-08-25 | 2008-11-05 | 惠氏公司 | 聚集蛋白聚糖酶结构 |
| GB0601976D0 (en) * | 2006-02-01 | 2006-03-15 | Merck Sharp & Dohme | Proteins |
| EP2027284A2 (en) * | 2006-05-18 | 2009-02-25 | Sanofi-Aventis | Use of adamts4 gene and protein polymorphisms |
| EP2455755A3 (en) * | 2007-06-22 | 2012-08-15 | GENERA ISTRAZIVANJA d.o.o. | Proteaoglycan-4 as marker for chronic renal failure |
| WO2009005033A1 (ja) * | 2007-06-29 | 2009-01-08 | National University Corporation Nagoya University | 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤 |
| EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
| PL3057992T3 (pl) | 2013-10-15 | 2024-08-26 | Genefrontier Corporation | Przeciwciało ludzkie przeciwko gatunkom ADAMTS typu agrekanazy do leczenia chorób związanych z agrekanazą |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3451575A (en) * | 1967-09-15 | 1969-06-24 | Geza Petro Jr | Conveyor bucket with hydraulically-operated grille-like lid |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| WO1986000639A1 (en) | 1984-07-06 | 1986-01-30 | Sandoz Ag | Lymphokine production and purification |
| ATE78515T1 (de) | 1984-10-05 | 1992-08-15 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| US6069229A (en) * | 1997-03-07 | 2000-05-30 | Schering Corporation | Mammalian proteinases; oxidoreductases; related reagents |
| AU8513198A (en) * | 1997-07-25 | 1999-02-16 | Du Pont Pharmaceuticals Company | Aggrecan degrading metallo proteases |
| US6842704B2 (en) * | 1998-02-04 | 2005-01-11 | Immunex Corporation | Crystalline TNF-α-converting enzyme and uses thereof |
| AU3622600A (en) * | 1999-03-08 | 2000-09-28 | Neurocrine Biosciences, Inc. | Metalloproteinases and methods of use therefor |
| US6391610B1 (en) * | 1999-08-06 | 2002-05-21 | The Cleveland Clinic Foundation | Nucleic acids encoding zinc metalloproteases |
| EP1136547A3 (en) | 2000-03-22 | 2002-09-25 | Pfizer Products Inc. | Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| US6458552B1 (en) * | 2000-06-06 | 2002-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Metalloprotease peptide substrates and methods |
| US20020151702A1 (en) * | 2000-10-18 | 2002-10-17 | Genetics Institute, Inc. | Aggrecanase molecules |
| SE0102298D0 (sv) * | 2001-06-27 | 2001-06-27 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| WO2003004607A2 (en) * | 2001-07-05 | 2003-01-16 | Wyeth | Aggrecanase molecules |
| US7037658B2 (en) | 2001-08-16 | 2006-05-02 | Regents Of University Of Michigan | Methods and compositions for detecting variant ADAMTS13 genes |
| US20030105313A1 (en) * | 2001-10-16 | 2003-06-05 | American Home Products Corporation | Aggrecanase molecules |
| JP2005515779A (ja) * | 2002-01-31 | 2005-06-02 | ワイス | アグレカナーゼ分子 |
| SG160194A1 (en) * | 2002-02-05 | 2010-04-29 | Wyeth Corp | Truncated aggrecanase molecules |
| MXPA05000959A (es) * | 2002-07-29 | 2005-05-16 | Wyeth Corp | Moleculas adamts4 modificadas y metodo de uso de las mismas. |
-
2003
- 2003-07-29 MX MXPA05000959A patent/MXPA05000959A/es unknown
- 2003-07-29 JP JP2004524915A patent/JP2005534308A/ja active Pending
- 2003-07-29 US US10/628,432 patent/US7118902B2/en not_active Expired - Fee Related
- 2003-07-29 AU AU2003261269A patent/AU2003261269A1/en not_active Withdrawn
- 2003-07-29 WO PCT/US2003/023484 patent/WO2004011637A2/en not_active Ceased
- 2003-07-29 CN CNA038184230A patent/CN1681920A/zh not_active Withdrawn
- 2003-07-29 EP EP03771941A patent/EP1525307A2/en not_active Withdrawn
- 2003-07-29 CA CA002492444A patent/CA2492444A1/en not_active Withdrawn
- 2003-07-29 BR BRPI0313083-5A patent/BR0313083A/pt not_active IP Right Cessation
-
2005
- 2005-01-27 IL IL16653505A patent/IL166535A0/xx unknown
-
2006
- 2006-06-12 US US11/451,006 patent/US20060228354A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11098368B2 (en) | ALK and NTRK1 fusion molecules and uses thereof | |
| Tomaszewski et al. | New pathways of mutational change in SARS-CoV-2 proteomes involve regions of intrinsic disorder important for virus replication and release | |
| Li | Structure, function, and evolution of coronavirus spike proteins | |
| Brockway et al. | Characterization of the expression, intracellular localization, and replication complex association of the putative mouse hepatitis virus RNA-dependent RNA polymerase | |
| Dautin et al. | Cleavage of a bacterial autotransporter by an evolutionarily convergent autocatalytic mechanism | |
| JP2005534308A5 (enExample) | ||
| US20220396604A1 (en) | Compositions comprising modified smarcb1 and uses thereof | |
| KR20150064104A (ko) | 사람 베타 코로나바이러스의 계통 c 및 이의 바이러스 수용체로서 n-말단 디펩티딜 펩티다아제의 확인 | |
| KR20160138494A (ko) | Fgfr 융합물 | |
| JP2010530238A5 (enExample) | ||
| Slavin et al. | Dephosphorylation of cyst wall proteins by a secreted lysosomal acid phosphatase is essential for excystation of Giardia lamblia | |
| Szklarczyk et al. | NDUFB7 and NDUFA8 are located at the intermembrane surface of complex I | |
| US20040043378A1 (en) | Methods of identifying modulators of bromodomains | |
| US12247978B2 (en) | Compositions and methods for detection and treatment of coronavirus infection | |
| JP2004536585A5 (enExample) | ||
| Chen et al. | hACE2-induced allosteric activation in SARS-CoV versus SARS-CoV-2 spike assemblies revealed by structural dynamics | |
| Chatterjee et al. | Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold | |
| Sekiguchi et al. | Basic fibroblast growth factor fused with tandem collagen‐binding domains from clostridium histolyticum collagenase ColG increases bone formation | |
| JP4383170B2 (ja) | ヒストン脱アセチル化酵素９ | |
| RU2004117536A (ru) | Новые изоформы ингибитора роста васкулярных эндотелиальных клеток | |
| Stincarelli et al. | SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein | |
| JP2008539164A (ja) | レプリキンペプチド及びその使用 | |
| CN113521286B (zh) | 冠状病毒蛋白酶抑制剂及其应用 | |
| JP2004537284A5 (enExample) | ||
| US6468755B1 (en) | Method for identifying compounds for treatment of insulin resistance |